BiologicalDrug
IBI311 clinical trials
Also written IBI311.
- studies test it
- 9
- open now
- 4
- in phase 3
- 4
- first study started
- 2022
Keep track of what changes. Save the IBI311 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
9 studies that test it; most in 2025 (4)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 2
- Phase 3
- 4
- Phase 4
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 4
Innovent Biologics (Suzhou) Co. Ltd. (5) · Shanghai Changzheng Hospital (3) · Peking University People's Hospital (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses IBI311 is read from its arms, and is right about nine times in ten.
Testing it · 9
- A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye DiseaseRecruitingPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT07113262Written as IBI311
- Efficacy and Safety of Sequential Hormone Therapy and Tetuzumab Therapy in Patients With Moderate to Severe TAO in the Active Stage After Glucocorticoid Treatment.RecruitingPhase 4Shanghai Changzheng HospitalNCT07152366Written as IBI311
- The Safety and Efficacy of Sequential Hormone Therapy and IBI311 Therapy in Patients With Active Moderate to Severe TAO in the Initial Treatment.RecruitingPhase 4Shanghai Changzheng HospitalNCT07152340Written as IBI311
- Evaluation of the Efficacy and Safety Observation of IBI311 Treatment in Patients With Inactive TAORecruitingPhase 4Shanghai Changzheng HospitalNCT07152392Written as IBI311
- A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye DiseaseCompletedPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT06126783Written as IBI311
- A Study of IBI311 in Subjects With Steroid-resistant, Thyroid Associated OphthalmopathyCompletedPhase 3Peking University People's HospitalNCT06269393Written as IBI311
- A Study of IBI311 in Subjects With Inactive or Active Thyroid Eye DiseaseCompletedPhase 2Innovent Biologics (Suzhou) Co. Ltd.NCT06525506Written as IBI311 (20 mg)
- A Study of IBI311 in Subjects With Active Thyroid Eye DiseaseCompletedPhase 2/3Innovent Biologics (Suzhou) Co. Ltd.NCT05795621Written as IBI311
- A Study of IBI311 in Healthy VolunteersCompletedPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT05480579Written as IBI311